Health
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
DURHAM, N.C., October 17, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE (GeSIDA 11720 study) showing that Dovato (dolutegravir/lamivudine [DTG/3TC]) is as effective as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically signifi
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":409,"url":"https://media.zenfs.com/en/business-wire.com/55da12c94ac81f0a6b0dae2fc7fb8c9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1HUYvL2XM60sinSmyE0RWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTgxODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/55da12c94ac81f0a6b0dae2fc7fb8c9b","width":480,"height":409}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) in virologically suppressed adults who switched from their prior regimen","length":271,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In latest data, Dovato led to significantly less weight gain and fewer drug-related adverse events compared to BIC/FTC/TAF through two years of follow-up","length":153,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":424,"olType":false},{"type":"text","content":"DURHAM, N.C., October 17, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE (GeSIDA 11720 study) showing that Dovato (dolutegravir/lamivudine [DTG/3TC]) is as effective as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically significant less weight gain and fewer drug-related adverse events over the two-year study period. Results will be presented at the European AIDS Clinical Society (EACS) annual congress, held in Paris, France (15-18 October).","length":735,"tagName":"p"},{"type":"text","content":"PASO DOBLE is the largest head-to-head, phase IV randomized clinical trial investigating the two-drug regimen Dovato compared to the three-drug regimen BIC/FTC/TAF for the treatment of HIV-1 in people who are virologically suppressed and could benefit from treatment optimization. Results at 96 weeks showed patients who switched to Dovato achieved non-inferior efficacy in maintaining viral suppressio...